Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | PRKCA | P17252 | 5/20 | 0.36 |
| ▸ | DNTT | P04053 | 1/20 | 0.35 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12474812 | 0.80 | PPARG (0.54) | PPARGCYP1A2PRKCA | |
| SCHEMBL12474810 | 0.80 | PPARG (0.54) | PPARGCYP1A2PRKCA | |
| SCHEMBL7054077 | 0.79 | CYP1A2 (0.44) | PPARGCYP1A2PRKCADNTTGRM2 | |
| SCHEMBL31493319 | 0.79 | CYP1A2 (0.44) | PPARGCYP1A2PRKCADNTTGRM2 | |
| SCHEMBL6118924 | 0.75 | CYP1A2 (0.76) | PPARGCYP1A2PRKCAGRM2 | |
| SCHEMBL15655925 | 0.75 | CYP1A2 (0.76) | PPARGCYP1A2PRKCAGRM2 | |
| SCHEMBL17848887 | 0.75 | CYP1A2 (0.76) | PPARGCYP1A2PRKCAGRM2 | |
| SCHEMBL15657520 | 0.75 | CYP1A2 (0.76) | PPARGCYP1A2PRKCAGRM2 | |
| SCHEMBL15655829 | 0.75 | CYP1A2 (0.76) | PPARGCYP1A2PRKCAGRM2 | |
| SCHEMBL6118667 | 0.75 | CYP1A2 (0.76) | PPARGCYP1A2PRKCAGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004107-A1 | Method for designing a pharmaceutical compound specific to a desired receptor, a designed compound thereby, and pharmaceutical compositions containing the same | OJIMA MASANORI | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004107-A1 | Method for designing a pharmaceutical compound specific to a desired receptor, a designed compound thereby, and pharmaceutical compositions containing the same | TBXA2R, PTAFR, PTGIR | PPARG 292/4885CYP1A2 1175/4885PRKCA 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.